

# Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Research Report 2024, Forecast to 2032

<https://marketpublishers.com/r/G114A7362AF8EN.html>

Date: October 2024

Pages: 166

Price: US\$ 3,400.00 (Single User License)

ID: G114A7362AF8EN

## Abstracts

### Report Overview

Non-alcoholic steatohepatitis (NASH) is a form of liver disease characterized by inflammation and liver cell damage caused by the accumulation of fat in the liver. It is often associated with obesity, insulin resistance, and metabolic syndrome. As there is currently no approved specific therapy for NASH, treatment primarily focuses on managing the underlying risk factors and minimizing liver damage.

The global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics market size was estimated at USD 1120 million in 2023 and is projected to reach USD 1990.82 million by 2032, exhibiting a CAGR of 6.60% during the forecast period.

North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics market size was estimated at USD 325.79 million in 2023, at a CAGR of 5.66% during the forecast period of 2024 through 2032.

This report provides a deep insight into the global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business

organization. The report structure also focuses on the competitive landscape of the Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics market in any manner.

### Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

#### Key Company

Allergan plc

Pfizer Inc

Gilead Sciences

Genfit SA

Novartis AG

Intercepts Pharmaceuticals

Cadila Healthcare

Novo Nordisk

Raptor Pharmaceutical Corp

Galmed Pharmaceuticals

Madrigal Pharmaceuticals

Viking Therapeutics

Conatus Pharmaceuticals

NGM Biopharmaceuticals

CymaBay Therapeutics

Boehringer Ingelheim

Eli Lilly and Company

Bristol Myers Squibb

Market Segmentation (by Type)

Imaging Techniques

Diagnostic Tests

Biopsy

Others

Market Segmentation (by Application)

Hospital Pharmacy

Online Channels

Retail Channels

Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market

Overview of the regional outlook of the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the

years to come

6-month post-sales analyst support

## Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

## Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.

Chapter 13 is the main points and conclusions of the report.

## Contents

### **1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE**

- 1.1 Market Definition and Statistical Scope of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics
- 1.2 Key Market Segments
  - 1.2.1 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Segment by Type
  - 1.2.2 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Segment by Application
- 1.3 Methodology & Sources of Information
  - 1.3.1 Research Methodology
  - 1.3.2 Research Process
  - 1.3.3 Market Breakdown and Data Triangulation
  - 1.3.4 Base Year
  - 1.3.5 Report Assumptions & Caveats

### **2 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET OVERVIEW**

- 2.1 Global Market Overview
  - 2.1.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD) Estimates and Forecasts (2019-2032)
  - 2.1.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Estimates and Forecasts (2019-2032)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region

### **3 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE**

- 3.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Manufacturers (2019-2024)
- 3.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue Market Share by Manufacturers (2019-2024)
- 3.3 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.4 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Average Price by Manufacturers (2019-2024)

3.5 Manufacturers Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Sites, Area Served, Product Type

3.6 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Competitive Situation and Trends

3.6.1 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Concentration Rate

3.6.2 Global 5 and 10 Largest Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Players Market Share by Revenue

3.6.3 Mergers & Acquisitions, Expansion

## **4 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS INDUSTRY CHAIN ANALYSIS**

4.1 Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

## **5 THE DEVELOPMENT AND DYNAMICS OF NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET**

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Market Restraints

5.5 Industry News

5.5.1 New Product Developments

5.5.2 Mergers & Acquisitions

5.5.3 Expansions

5.5.4 Collaboration/Supply Contracts

5.6 Industry Policies

## **6 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET SEGMENTATION BY TYPE**

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Type (2019-2024)

6.3 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size

Market Share by Type (2019-2024)

6.4 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Price by Type (2019-2024)

## **7 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET SEGMENTATION BY APPLICATION**

7.1 Evaluation Matrix of Segment Market Development Potential (Application)

7.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Sales by Application (2019-2024)

7.3 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD) by Application (2019-2024)

7.4 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Growth Rate by Application (2019-2024)

## **8 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET CONSUMPTION BY REGION**

8.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region

8.1.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region

8.1.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Region

8.2 North America

8.2.1 North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country

8.2.2 U.S.

8.2.3 Canada

8.2.4 Mexico

8.3 Europe

8.3.1 Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country

8.3.2 Germany

8.3.3 France

8.3.4 U.K.

8.3.5 Italy

8.3.6 Russia

8.4 Asia Pacific

8.4.1 Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales

by Region

8.4.2 China

8.4.3 Japan

8.4.4 South Korea

8.4.5 India

8.4.6 Southeast Asia

8.5 South America

8.5.1 South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics

Sales by Country

8.5.2 Brazil

8.5.3 Argentina

8.5.4 Columbia

8.6 Middle East and Africa

8.6.1 Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and

Diagnostics Sales by Region

8.6.2 Saudi Arabia

8.6.3 UAE

8.6.4 Egypt

8.6.5 Nigeria

8.6.6 South Africa

## **9 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET PRODUCTION BY REGION**

9.1 Global Production of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Region (2019-2024)

9.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue Market Share by Region (2019-2024)

9.3 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production, Revenue, Price and Gross Margin (2019-2024)

9.4 North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production

9.4.1 North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production Growth Rate (2019-2024)

9.4.2 North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production, Revenue, Price and Gross Margin (2019-2024)

9.5 Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production

9.5.1 Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production Growth Rate (2019-2024)

9.5.2 Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production, Revenue, Price and Gross Margin (2019-2024)

9.6 Japan Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (2019-2024)

9.6.1 Japan Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production Growth Rate (2019-2024)

9.6.2 Japan Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production, Revenue, Price and Gross Margin (2019-2024)

9.7 China Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (2019-2024)

9.7.1 China Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production Growth Rate (2019-2024)

9.7.2 China Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production, Revenue, Price and Gross Margin (2019-2024)

## **10 KEY COMPANIES PROFILE**

10.1 Allergan plc

10.1.1 Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

10.1.2 Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

10.1.3 Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance

10.1.4 Allergan plc Business Overview

10.1.5 Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis

10.1.6 Allergan plc Recent Developments

10.2 Pfizer Inc

10.2.1 Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

10.2.2 Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

10.2.3 Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance

10.2.4 Pfizer Inc Business Overview

10.2.5 Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis

10.2.6 Pfizer Inc Recent Developments

## 10.3 Gilead Sciences

10.3.1 Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics  
Basic Information

10.3.2 Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics  
Product Overview

10.3.3 Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics  
Product Market Performance

10.3.4 Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics  
SWOT Analysis

10.3.5 Gilead Sciences Business Overview

10.3.6 Gilead Sciences Recent Developments

## 10.4 Genfit SA

10.4.1 Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic  
Information

10.4.2 Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product  
Overview

10.4.3 Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product  
Market Performance

10.4.4 Genfit SA Business Overview

10.4.5 Genfit SA Recent Developments

## 10.5 Novartis AG

10.5.1 Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic  
Information

10.5.2 Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics  
Product Overview

10.5.3 Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics  
Product Market Performance

10.5.4 Novartis AG Business Overview

10.5.5 Novartis AG Recent Developments

## 10.6 Intercepts Pharmaceuticals

10.6.1 Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and  
Diagnostics Basic Information

10.6.2 Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and  
Diagnostics Product Overview

10.6.3 Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and  
Diagnostics Product Market Performance

10.6.4 Intercepts Pharmaceuticals Business Overview

10.6.5 Intercepts Pharmaceuticals Recent Developments

## 10.7 Cadila Healthcare

10.7.1 Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics  
Basic Information

10.7.2 Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics  
Product Overview

10.7.3 Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics  
Product Market Performance

10.7.4 Cadila Healthcare Business Overview

10.7.5 Cadila Healthcare Recent Developments

10.8 Novo Nordisk

10.8.1 Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics  
Basic Information

10.8.2 Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics  
Product Overview

10.8.3 Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics  
Product Market Performance

10.8.4 Novo Nordisk Business Overview

10.8.5 Novo Nordisk Recent Developments

10.9 Raptor Pharmaceutical Corp

10.9.1 Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and  
Diagnostics Basic Information

10.9.2 Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and  
Diagnostics Product Overview

10.9.3 Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and  
Diagnostics Product Market Performance

10.9.4 Raptor Pharmaceutical Corp Business Overview

10.9.5 Raptor Pharmaceutical Corp Recent Developments

10.10 Galmed Pharmaceuticals

10.10.1 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and  
Diagnostics Basic Information

10.10.2 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and  
Diagnostics Product Overview

10.10.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and  
Diagnostics Product Market Performance

10.10.4 Galmed Pharmaceuticals Business Overview

10.10.5 Galmed Pharmaceuticals Recent Developments

10.11 Madrigal Pharmaceuticals

10.11.1 Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and  
Diagnostics Basic Information

10.11.2 Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and

## Diagnostics Product Overview

10.11.3 Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance

10.11.4 Madrigal Pharmaceuticals Business Overview

10.11.5 Madrigal Pharmaceuticals Recent Developments

## 10.12 Viking Therapeutics

10.12.1 Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

10.12.2 Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

10.12.3 Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance

10.12.4 Viking Therapeutics Business Overview

10.12.5 Viking Therapeutics Recent Developments

## 10.13 Conatus Pharmaceuticals

10.13.1 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

10.13.2 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

10.13.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance

10.13.4 Conatus Pharmaceuticals Business Overview

10.13.5 Conatus Pharmaceuticals Recent Developments

## 10.14 NGM Biopharmaceuticals

10.14.1 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

10.14.2 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

10.14.3 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance

10.14.4 NGM Biopharmaceuticals Business Overview

10.14.5 NGM Biopharmaceuticals Recent Developments

## 10.15 CymaBay Therapeutics

10.15.1 CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

10.15.2 CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

10.15.3 CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance

- 10.15.4 CymaBay Therapeutics Business Overview
- 10.15.5 CymaBay Therapeutics Recent Developments
- 10.16 Boehringer Ingelheim
  - 10.16.1 Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
  - 10.16.2 Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
  - 10.16.3 Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
  - 10.16.4 Boehringer Ingelheim Business Overview
  - 10.16.5 Boehringer Ingelheim Recent Developments
- 10.17 Eli Lilly and Company
  - 10.17.1 Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
  - 10.17.2 Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
  - 10.17.3 Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
  - 10.17.4 Eli Lilly and Company Business Overview
  - 10.17.5 Eli Lilly and Company Recent Developments
- 10.18 Bristol Myers Squibb
  - 10.18.1 Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information
  - 10.18.2 Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview
  - 10.18.3 Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Market Performance
  - 10.18.4 Bristol Myers Squibb Business Overview
  - 10.18.5 Bristol Myers Squibb Recent Developments

## **11 NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST BY REGION**

- 11.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast
- 11.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Forecast by Region
  - 11.2.1 North America Market Size Forecast by Country
  - 11.2.2 Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market

## Size Forecast by Country

### 11.2.3 Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market

## Size Forecast by Region

### 11.2.4 South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics

## Market Size Forecast by Country

### 11.2.5 Middle East and Africa Forecasted Consumption of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Country

## **12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)**

### 12.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Forecast by Type (2025-2032)

#### 12.1.1 Global Forecasted Sales of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type (2025-2032)

#### 12.1.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Type (2025-2032)

#### 12.1.3 Global Forecasted Price of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type (2025-2032)

### 12.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Forecast by Application (2025-2032)

#### 12.2.1 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) Forecast by Application

#### 12.2.2 Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD) Forecast by Application (2025-2032)

## **13 CONCLUSION AND KEY FINDINGS**

## List Of Tables

### LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Comparison by Region (M USD)

Table 5. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) by Manufacturers (2019-2024)

Table 6. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Manufacturers (2019-2024)

Table 7. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue (M USD) by Manufacturers (2019-2024)

Table 8. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue Share by Manufacturers (2019-2024)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics as of 2022)

Table 10. Global Market Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Average Price (USD/Unit) of Key Manufacturers (2019-2024)

Table 11. Manufacturers Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Sites and Area Served

Table 12. Manufacturers Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Type

Table 13. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Industry Chain Map of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics

Table 16. Market Overview of Key Raw Materials

Table 17. Midstream Market Analysis

Table 18. Downstream Customer Analysis

Table 19. Key Development Trends

Table 20. Driving Factors

Table 21. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Challenges

Table 22. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Type (K Units)

Table 23. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size by Type (M USD)

Table 24. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) by Type (2019-2024)

Table 25. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Type (2019-2024)

Table 26. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD) by Type (2019-2024)

Table 27. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Share by Type (2019-2024)

Table 28. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Price (USD/Unit) by Type (2019-2024)

Table 29. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) by Application

Table 30. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size by Application

Table 31. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Application (2019-2024) & (K Units)

Table 32. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Application (2019-2024)

Table 33. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Application (2019-2024) & (M USD)

Table 34. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Application (2019-2024)

Table 35. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Growth Rate by Application (2019-2024)

Table 36. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region (2019-2024) & (K Units)

Table 37. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Region (2019-2024)

Table 38. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country (2019-2024) & (K Units)

Table 39. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country (2019-2024) & (K Units)

Table 40. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Region (2019-2024) & (K Units)

Table 41. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales by Country (2019-2024) & (K Units)

Table 42. Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and

Diagnostics Sales by Region (2019-2024) & (K Units)

Table 43. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics

Production (K Units) by Region (2019-2024)

Table 44. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue (US\$ Million) by Region (2019-2024)

Table 45. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue Market Share by Region (2019-2024)

Table 46. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 47. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 48. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 49. Japan Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 50. China Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 51. Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

Table 52. Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

Table 53. Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 54. Allergan plc Business Overview

Table 55. Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis

Table 56. Allergan plc Recent Developments

Table 57. Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

Table 58. Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

Table 59. Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 60. Pfizer Inc Business Overview

Table 61. Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT

## Analysis

Table 62. Pfizer Inc Recent Developments

Table 63. Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

Table 64. Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

Table 65. Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 66. Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics SWOT Analysis

Table 67. Gilead Sciences Business Overview

Table 68. Gilead Sciences Recent Developments

Table 69. Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

Table 70. Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

Table 71. Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 72. Genfit SA Business Overview

Table 73. Genfit SA Recent Developments

Table 74. Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

Table 75. Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

Table 76. Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 77. Novartis AG Business Overview

Table 78. Novartis AG Recent Developments

Table 79. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

Table 80. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

Table 81. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 82. Intercept Pharmaceuticals Business Overview

Table 83. Intercept Pharmaceuticals Recent Developments

Table 84. Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

Table 85. Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

Table 86. Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 87. Cadila Healthcare Business Overview

Table 88. Cadila Healthcare Recent Developments

Table 89. Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

Table 90. Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

Table 91. Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 92. Novo Nordisk Business Overview

Table 93. Novo Nordisk Recent Developments

Table 94. Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

Table 95. Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

Table 96. Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 97. Raptor Pharmaceutical Corp Business Overview

Table 98. Raptor Pharmaceutical Corp Recent Developments

Table 99. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

Table 100. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

Table 101. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 102. Galmed Pharmaceuticals Business Overview

Table 103. Galmed Pharmaceuticals Recent Developments

Table 104. Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

Table 105. Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

Table 106. Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin

(2019-2024)

Table 107. Madrigal Pharmaceuticals Business Overview

Table 108. Madrigal Pharmaceuticals Recent Developments

Table 109. Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

Table 110. Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

Table 111. Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 112. Viking Therapeutics Business Overview

Table 113. Viking Therapeutics Recent Developments

Table 114. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

Table 115. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

Table 116. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 117. Conatus Pharmaceuticals Business Overview

Table 118. Conatus Pharmaceuticals Recent Developments

Table 119. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

Table 120. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

Table 121. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 122. NGM Biopharmaceuticals Business Overview

Table 123. NGM Biopharmaceuticals Recent Developments

Table 124. CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

Table 125. CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

Table 126. CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 127. CymaBay Therapeutics Business Overview

Table 128. CymaBay Therapeutics Recent Developments

Table 129. Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

Table 130. Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

Table 131. Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 132. Boehringer Ingelheim Business Overview

Table 133. Boehringer Ingelheim Recent Developments

Table 134. Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

Table 135. Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

Table 136. Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 137. Eli Lilly and Company Business Overview

Table 138. Eli Lilly and Company Recent Developments

Table 139. Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Basic Information

Table 140. Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Overview

Table 141. Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 142. Bristol Myers Squibb Business Overview

Table 143. Bristol Myers Squibb Recent Developments

Table 144. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Region (2025-2032) & (K Units)

Table 145. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Region (2025-2032) & (M USD)

Table 146. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Country (2025-2032) & (K Units)

Table 147. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country (2025-2032) & (M USD)

Table 148. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Country (2025-2032) & (K Units)

Table 149. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country (2025-2032) & (M USD)

Table 150. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Region (2025-2032) & (K Units)

Table 151. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Region (2025-2032) & (M USD)

Table 152. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Country (2025-2032) & (K Units)

Table 153. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country (2025-2032) & (M USD)

Table 154. Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Consumption Forecast by Country (2025-2032) & (Units)

Table 155. Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Country (2025-2032) & (M USD)

Table 156. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Type (2025-2032) & (K Units)

Table 157. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Type (2025-2032) & (M USD)

Table 158. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Price Forecast by Type (2025-2032) & (USD/Unit)

Table 159. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) Forecast by Application (2025-2032)

Table 160. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Application (2025-2032) & (M USD)

## List Of Figures

### LIST OF FIGURES

Figure 1. Product Picture of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics

Figure 2. Data Triangulation

Figure 3. Key Caveats

Figure 4. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD), 2019-2032

Figure 5. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size (M USD) (2019-2032)

Figure 6. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) & (2019-2032)

Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 9. Evaluation Matrix of Regional Market Development Potential

Figure 10. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size by Country (M USD)

Figure 11. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Share by Manufacturers in 2023

Figure 12. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue Share by Manufacturers in 2023

Figure 13. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023

Figure 14. Global Market Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Average Price (USD/Unit) of Key Manufacturers in 2023

Figure 15. The Global 5 and 10 Largest Players: Market Share by Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue in 2023

Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 17. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Type

Figure 18. Sales Market Share of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type (2019-2024)

Figure 19. Sales Market Share of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type in 2023

Figure 20. Market Size Share of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type (2019-2024)

Figure 21. Market Size Market Share of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics by Type in 2023

Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 23. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Application

Figure 24. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Application (2019-2024)

Figure 25. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Application in 2023

Figure 26. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Application (2019-2024)

Figure 27. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Application in 2023

Figure 28. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Growth Rate by Application (2019-2024)

Figure 29. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Region (2019-2024)

Figure 30. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)

Figure 31. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Country in 2023

Figure 32. U.S. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)

Figure 33. Canada Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (K Units) and Growth Rate (2019-2024)

Figure 34. Mexico Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales (Units) and Growth Rate (2019-2024)

Figure 35. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)

Figure 36. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Country in 2023

Figure 37. Germany Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)

Figure 38. France Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)

Figure 39. U.K. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)

Figure 40. Italy Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)

Figure 41. Russia Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)

Figure 42. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (K Units)

Figure 43. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Region in 2023

Figure 44. China Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)

Figure 45. Japan Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)

Figure 46. South Korea Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)

Figure 47. India Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)

Figure 48. Southeast Asia Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)

Figure 49. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (K Units)

Figure 50. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Country in 2023

Figure 51. Brazil Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)

Figure 52. Argentina Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)

Figure 53. Columbia Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)

Figure 54. Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (K Units)

Figure 55. Middle East and Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share by Region in 2023

Figure 56. Saudi Arabia Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)

Figure 57. UAE Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)

Figure 58. Egypt Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)

Figure 59. Nigeria Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)

Figure 60. South Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales and Growth Rate (2019-2024) & (K Units)

Figure 61. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics

Production Market Share by Region (2019-2024)

Figure 62. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (K Units) Growth Rate (2019-2024)

Figure 63. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (K Units) Growth Rate (2019-2024)

Figure 64. Japan Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (K Units) Growth Rate (2019-2024)

Figure 65. China Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Production (K Units) Growth Rate (2019-2024)

Figure 66. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Volume (2019-2032) & (K Units)

Figure 67. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size Forecast by Value (2019-2032) & (M USD)

Figure 68. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share Forecast by Type (2025-2032)

Figure 69. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share Forecast by Type (2025-2032)

Figure 70. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Forecast by Application (2025-2032)

Figure 71. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share Forecast by Application (2025-2032)

## I would like to order

Product name: Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Research Report 2024, Forecast to 2032

Product link: <https://marketpublishers.com/r/G114A7362AF8EN.html>

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G114A7362AF8EN.html>